Tania Da Silva1, Sina Hafizi1, Jeremy J Watts1,2, Cynthia Shannon Weickert3,4,5, Jeffrey H Meyer1,2,6,7, Sylvain Houle1,6,7, Pablo Rusjan1,6,7, Romina Mizrahi1,2,6,7. 1. Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada. 2. Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada. 3. Schizophrenia Research Laboratory, Neuroscience Research Australia, Randwick, New South Wales, Australia. 4. School of Psychiatry, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia. 5. Department of Neuroscience and Physiology, Upstate Medical University, Syracuse, New York. 6. Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada. 7. Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Abstract
Importance: Cannabis is the most commonly used illicit drug in the world. Cannabinoids have been shown to modulate immune responses; however, the association of cannabis with neuroimmune function has never been investigated in vivo in the human brain. Objective: To investigate neuroimmune activation or 18-kDa translocator protein (TSPO) levels in long-term cannabis users, and to evaluate the association of brain TSPO levels with behavioral measures and inflammatory blood biomarkers. Design, Setting, and Participants: This cross-sectional study based in Toronto, Ontario, recruited individuals from January 1, 2015, to October 30, 2018. Participants included long-term cannabis users (n = 24) and non-cannabis-using controls (n = 27). Cannabis users were included if they had a positive urine drug screen for only cannabis and if they used cannabis at least 4 times per week for the past 12 months and/or met the criteria for cannabis use disorder. All participants underwent a positron emission tomography scan with [18F]FEPPA, or fluorine F 18-labeled N-(2-(2-fluoroethoxy)benzyl)-N-(4-phenoxypyridin-3-yl)acetamide. Main Outcomes and Measures: Total distribution volume was quantified across regions of interest. Stress and anxiety as well as peripheral measures of inflammatory cytokines and C-reactive protein levels were also measured. Results: In total, 24 long-term cannabis users (mean [SD] age, 23.1 [3.8] years; 15 men [63%]) and 27 non-cannabis-using controls (mean [SD] age, 23.6 [4.2] years; 18 women [67%]) were included and completed all study procedures. Compared with the controls, cannabis users had higher [18F]FEPPA total distribution volume (main group effect: F1,48 = 6.5 [P = .01]; ROI effect: F1,200 = 28.4 [P < .001]; Cohen d = 0.6; 23.3% higher), with a more prominent implication for the cannabis use disorder subgroup (n = 15; main group effect: F1,39 = 8.5 [P = .006]; ROI effect: F1,164 = 19.3 [P < .001]; Cohen d = 0.8; 31.5% higher). Greater TSPO levels in the brain were associated with stress and anxiety and with higher circulating C-reactive protein levels in cannabis users. Conclusions and Relevance: The results of this study suggest that TSPO levels in cannabis users, particularly in those with cannabis use disorder, are higher than those in non-cannabis-using controls. The findings emphasize the need for more complementary preclinical systems for a better understanding of the role of cannabinoids and TSPO in neuroimmune signaling.
Importance: Cannabis is the most commonly used illicit drug in the world. Cannabinoids have been shown to modulate immune responses; however, the association of cannabis with neuroimmune function has never been investigated in vivo in the human brain. Objective: To investigate neuroimmune activation or 18-kDa translocator protein (TSPO) levels in long-term cannabis users, and to evaluate the association of brain TSPO levels with behavioral measures and inflammatory blood biomarkers. Design, Setting, and Participants: This cross-sectional study based in Toronto, Ontario, recruited individuals from January 1, 2015, to October 30, 2018. Participants included long-term cannabis users (n = 24) and non-cannabis-using controls (n = 27). Cannabis users were included if they had a positive urine drug screen for only cannabis and if they used cannabis at least 4 times per week for the past 12 months and/or met the criteria for cannabis use disorder. All participants underwent a positron emission tomography scan with [18F]FEPPA, or fluorine F 18-labeled N-(2-(2-fluoroethoxy)benzyl)-N-(4-phenoxypyridin-3-yl)acetamide. Main Outcomes and Measures: Total distribution volume was quantified across regions of interest. Stress and anxiety as well as peripheral measures of inflammatory cytokines and C-reactive protein levels were also measured. Results: In total, 24 long-term cannabis users (mean [SD] age, 23.1 [3.8] years; 15 men [63%]) and 27 non-cannabis-using controls (mean [SD] age, 23.6 [4.2] years; 18 women [67%]) were included and completed all study procedures. Compared with the controls, cannabis users had higher [18F]FEPPA total distribution volume (main group effect: F1,48 = 6.5 [P = .01]; ROI effect: F1,200 = 28.4 [P < .001]; Cohen d = 0.6; 23.3% higher), with a more prominent implication for the cannabis use disorder subgroup (n = 15; main group effect: F1,39 = 8.5 [P = .006]; ROI effect: F1,164 = 19.3 [P < .001]; Cohen d = 0.8; 31.5% higher). Greater TSPO levels in the brain were associated with stress and anxiety and with higher circulating C-reactive protein levels in cannabis users. Conclusions and Relevance: The results of this study suggest that TSPO levels in cannabis users, particularly in those with cannabis use disorder, are higher than those in non-cannabis-using controls. The findings emphasize the need for more complementary preclinical systems for a better understanding of the role of cannabinoids and TSPO in neuroimmune signaling.
Authors: Arthur L Brody; Robert Hubert; Ryutaro Enoki; Lizette Y Garcia; Michael S Mamoun; Kyoji Okita; Edythe D London; Erika L Nurmi; Lauren C Seaman; Mark A Mandelkern Journal: Neuropsychopharmacology Date: 2017-03-06 Impact factor: 7.853
Authors: J M Coughlin; Y Wang; E B Ambinder; R E Ward; I Minn; M Vranesic; P K Kim; C N Ford; C Higgs; L N Hayes; D J Schretlen; R F Dannals; M Kassiou; A Sawa; M G Pomper Journal: Transl Psychiatry Date: 2016-04-12 Impact factor: 6.222
Authors: Jeffrey H Meyer; Simon Cervenka; Min-Jeong Kim; William C Kreisl; Ioline D Henter; Robert B Innis Journal: Lancet Psychiatry Date: 2020-10-21 Impact factor: 27.083
Authors: Giulia Cisbani; Alex Koppel; Adam H Metherel; Mackenzie E Smith; Kankana N Aji; Ana C Andreazza; Romina Mizrahi; Richard P Bazinet Journal: Lipids Date: 2022-01-24 Impact factor: 1.880
Authors: Dominic Simpson; Avideh Gharehgazlou; Tania Da Silva; Charlotte Labrie-Cleary; Alan A Wilson; Jeffrey H Meyer; Romina Mizrahi; Pablo M Rusjan Journal: Neuropsychopharmacology Date: 2022-04-05 Impact factor: 7.853
Authors: Gausiha Rathitharan; Jennifer Truong; Junchao Tong; Tina McCluskey; Jeffrey H Meyer; Romina Mizrahi; Jerry Warsh; Pablo Rusjan; James L Kennedy; Sylvain Houle; Stephen J Kish; Isabelle Boileau Journal: Addict Biol Date: 2020-02-04 Impact factor: 4.280
Authors: Cory Gerritsen; Yajur Iyengar; Tania DaSilva; Alex Koppel; Pablo Rusjan; R Michael Bagby; Romina Mizrahi Journal: Personal Neurosci Date: 2020-11-24
Authors: Maya R Jacobson; Jeremy J Watts; Tania Da Silva; Rachel F Tyndale; Pablo M Rusjan; Sylvain Houle; Alan A Wilson; Ruth A Ross; Isabelle Boileau; Romina Mizrahi Journal: Addict Biol Date: 2020-01-20 Impact factor: 4.280